Clinical trials with oncolytic measles virus: Current status and future prospects

Pavlos Msaouel, Mateusz Opyrchal, Angela Dispenzieri, Kah Whye Peng, Mark J. Federspiel, Stephen J. Russell, Evanthia Galanis

Research output: Contribution to journalReview article

25 Scopus citations

Abstract

Attenuated Edmonston lineage measles virus (MV-Edm) vaccine strains can preferentially infect and lyse a wide variety of cancer cells. Oncolytic MV-Edm derivatives are genetically engineered to express the human carcinoembryonic antigen (MV-CEA virus) or the human sodium iodide symporter (MV-NIS virus) and are currently being tested in clinical trials against ovarian cancer, glioblastoma multiforme, multiple myeloma, mesothelioma, head and neck cancer, breast cancer and malignant peripheral nerve sheath tumors. This review describes the basic and preclinical data that facilitated the clinical translation of MV-Edm strains, and summarizes the clinical results of this oncolytic platform to date. Furthermore, we discuss the latest clinically relevant MV-Edm vector developments and creative strategies for future translational steps.

Original languageEnglish
Pages (from-to)177-187
Number of pages11
JournalCurrent Cancer Drug Targets
Volume18
Issue number2
DOIs
StatePublished - Jan 1 2018
Externally publishedYes

Keywords

  • Cancer gene therapy
  • MV-CEA
  • MV-NIS
  • Measles virus clinical trials
  • Oncolytic measles
  • Virotherapy

Fingerprint Dive into the research topics of 'Clinical trials with oncolytic measles virus: Current status and future prospects'. Together they form a unique fingerprint.

  • Cite this

    Msaouel, P., Opyrchal, M., Dispenzieri, A., Peng, K. W., Federspiel, M. J., Russell, S. J., & Galanis, E. (2018). Clinical trials with oncolytic measles virus: Current status and future prospects. Current Cancer Drug Targets, 18(2), 177-187. https://doi.org/10.2174/1568009617666170222125035